These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 3841382

  • 1. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.
    Fiedler VB, Mardin M, Perzborn E, Grützmann R.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):267-74. PubMed ID: 3841382
    [Abstract] [Full Text] [Related]

  • 2. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ, Parratt JR.
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [Abstract] [Full Text] [Related]

  • 3. The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.
    Fiedler VB.
    Basic Res Cardiol; 1983 Jan; 78(3):266-80. PubMed ID: 6615399
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of canine coronary collateral flow by nafazatrom.
    Fiedler VB, Mardin M.
    Eur J Pharmacol; 1986 Nov 04; 130(3):157-67. PubMed ID: 3792445
    [Abstract] [Full Text] [Related]

  • 5. Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
    Fiedler VB.
    J Cardiovasc Pharmacol; 1984 Nov 04; 6(2):318-24. PubMed ID: 6200722
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ, Murtagh JJ, Jolly SR, Abrams GD, Pitt B, Lucchesi BR.
    Eur J Pharmacol; 1984 Jun 15; 102(1):63-70. PubMed ID: 6479219
    [Abstract] [Full Text] [Related]

  • 7. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB, Mardin M.
    J Cardiovasc Pharmacol; 1985 Jun 15; 7(5):983-9. PubMed ID: 2413312
    [Abstract] [Full Text] [Related]

  • 8. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
    Imamoto T, Terashita Z, Tanabe M, Nishikawa K, Hirata M.
    J Cardiovasc Pharmacol; 1986 Jun 15; 8(4):832-9. PubMed ID: 2427826
    [Abstract] [Full Text] [Related]

  • 9. Failure of nafazatrom to reduce infarct size and arrhythmias in a porcine model of acute coronary occlusion.
    Fiedler VB.
    Eur J Pharmacol; 1985 Aug 15; 114(2):189-95. PubMed ID: 3930268
    [Abstract] [Full Text] [Related]

  • 10. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
    Bednar M, Smith B, Pinto A, Mullane KM.
    Circ Res; 1985 Jul 15; 57(1):131-41. PubMed ID: 2988818
    [Abstract] [Full Text] [Related]

  • 11. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L, Mehta J, Mehta P.
    Am Heart J; 1985 May 15; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [Abstract] [Full Text] [Related]

  • 12. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR.
    Am Heart J; 1984 Apr 15; 107(4):629-37. PubMed ID: 6702555
    [Abstract] [Full Text] [Related]

  • 13. Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
    Toda I, Nozaki A, Kawakubo K, Murakawa Y, Inoue H, Yoshimoto N, Sugimoto T.
    Jpn Heart J; 1990 Jan 15; 31(1):87-97. PubMed ID: 2335849
    [Abstract] [Full Text] [Related]

  • 14. Lipoxygenase inhibitor nafazatrom fails to attenuate postischaemic ventricular dysfunction.
    O'Neill PG, Charlat ML, Kim HS, Pocius J, Michael LH, Hartley CJ, Zhu WX, Roberts R, Bolli R.
    Cardiovasc Res; 1987 Oct 15; 21(10):755-60. PubMed ID: 3125975
    [Abstract] [Full Text] [Related]

  • 15. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G, Bayorh MA, Stull R, Goldstein DS, Zerbe RL, Ramwell PW, Faden AI.
    Circ Shock; 1985 Oct 15; 17(3):223-32. PubMed ID: 3841032
    [Abstract] [Full Text] [Related]

  • 16. Do alterations in prostanoid or catecholamine release influence the antiarrhythmic activity of nicergoline?
    Williams FM, Coker SJ, Dean HG, Kane KA, Parratt JR.
    J Cardiovasc Pharmacol; 1986 Oct 15; 8(2):286-93. PubMed ID: 2422466
    [Abstract] [Full Text] [Related]

  • 17. Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death.
    Fiedler VB, Mardin M.
    Basic Res Cardiol; 1986 Oct 15; 81(1):40-53. PubMed ID: 3521579
    [Abstract] [Full Text] [Related]

  • 18. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.
    Buchanan MR, Butt RW, Turpie AG.
    Am Heart J; 1987 May 15; 113(5):1133-7. PubMed ID: 2953219
    [Abstract] [Full Text] [Related]

  • 19. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury.
    Hohlfeld T, Strobach H, Schrör K.
    J Pharmacol Exp Ther; 1993 Jan 15; 264(1):397-405. PubMed ID: 8423539
    [Abstract] [Full Text] [Related]

  • 20. Occlusion and reperfusion-induced arrhythmias in rats: involvement of platelets and effects of calcium antagonists.
    Swies J, Omogbai EK, Smith GM.
    J Cardiovasc Pharmacol; 1990 May 15; 15(5):816-25. PubMed ID: 1692943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.